Monthly Maintenance Items for FormsNet3

Each month the FormsNet3 team makes updates to validations, question enabling/disabling and form generation.
The monthly maintenance updates are tentatively scheduled for the 4th Friday of the month.

April 2025 (Released April 18, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9		Validation (Delete)	A validation exists within the organ impairment section that states if the visit is 100D, previously reported cannot be answered	Validation removed	The organ impairment section was recently revised and centers are instructed to report previously reported if the impairment was diagnosed prior to the infusion and persisted into the follow-up reporting period
F2013 r4	Q105	Validation (Modify)	Q105 Did the recipient have known nodal involvement? Must be answered	Updated validation to disable last evaluation section when CLL transformed to NHL	Questions are no longer applicable since the disease transformed
F2003 r2	Q11-15	Floating Text (Add)		Q11-15 will now allow multiple instances for reporting multiple mobilizations of the product	Reduce form burden for these commercial products
F2100 r9 and F4100 r9		Validation (Modify)		Improvements to the functionality of several validations using the recipient’s age on the date of contact (ex. height/weight, pregnancy)	Updating the questions to use new interactive disabling functionality so the validations work correctly with the contact date
F2450 r8		Validation (Add)		Adding a rule: date of diagnosis of chronic GVHD must be after date of diagnosis of acute GVHD	Consistency amongst forms (similar validation exists on the 2100)

March 2025 (Released March 28, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r9	Q503	Validation (add)	There is no validation for Q503 currently	If and only if Q513 (Specify histiocytic disorder classification) = Other pigmentary dilution disorder, then Q503 (Specify other pigmentary dilution disorder) must be answered	Q503 should be answered if “Other pigmentary dilution disorder” is selected in Q513

February 2025 (released February 21, 2025)

F2157 r1 Q281-284: When option value of “none” was selected on Q281 & Q283, date assessed Q282 & Q284 were not enabling. Corrections were made so questions would enable correctly.

January 2025 (released January 24, 2025)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2130 r4	Q66	Validation (Modify)	If and only if F2402 Q492 is equal to no, then Q66 must be answered	If and only if visit is equal to any (100D, 6M, 1Y, 2Y), then Q66 must be answered	Updated to align with Forms Instruction Manual
F2402 r9	Q425	Floating Text (Modify)	Instructional text above Q425: “Labs at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q425: “Labs at diagnosis”	Updated to align with Forms Instruction Manual
	Q429		Instructional text above Q429: “I.S.S. at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q429: “I.S.S. at diagnosis”
	Q431		Instructional text above Q431: “R-I.S.S. at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q431: “R-I.S.S. at diagnosis”
	Q433		Instructional text above Q433: “Labs at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q433: “Labs at diagnosis, or if subsequent infusion, report based on last evaluation prior to the start of the preparative regimen / infusion”
	Q441		Instructional text above Q441: “Labs at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Instructional text above Q441: “Labs at diagnosis”
			Floating text within Q441: “at diagnosis, or if subsequent infusion, report based on last relapse / progression prior to this infusion”	Floating text within Q441: “at diagnosis”

December 2024 (released December 13th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9	Q1	Validation (Modify)	Q1 must be answered	Q1 must be answered and no override allowed	Align F2100, F2450 and F4100
F2450 r8	Q1		Q1 must be answered	Q1 must be answered and no override allowed
F4100 r9	Q3		Q3 must be answered	Q3 must be answered and no override allowed

November 2024 (released November 15th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r6 & r7		Validation (Modify)	Atypical CML capturing WBC at diagnosis	Atypical CML does not capture WBC at diagnosis	Data quality improvement

October 2024 (released October 25th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2158 r2	Q16	Validation (Modify)	Q16 must be answered	Q16 is disabled for CS22-24 study participants	CS22-24 study patients will receive additional F3505 for each reporting period therefore duplicate RBC transfusion questions will be disabled on F2158.

September 2024 (released September 27th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4100 r9	Q21	Validation (Modify)	If and only if visit is equal to 100 day, then Q21 must be answered.	If and only if F2400 Q79 is not answered or F2400 Q79 is not equal to Betibeglo or Elivaldo and visit is equal to 100 day, then Q21 must be answered	Growth factor questions are asked on F2545 and F2547 therefore Q21 will be disabled on F2100 for study participants.

Additional Note: Forms 2544 r1, 2545 r1, 2546 r1, 2547 r1 and 3503 r1 were made active with the monthly maintenance updates on September 27th, 2024.

August 2024 (released August 23rd, 2024)

No updates to communicate.

July 2024 (released July 26th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4100 r9	Q4 & 5-11	Validation (Modify)	Q4 is disabled and Q5-11 are enabled	Q4 is enabled, Q5-11 are disabled	Align with changes to infusion reporting workflow
F2100 r9	Q3 & 4-9	Validation (Modify)	Q3 is disabled and Q4-9 are enabled	Q3 is enabled and Q4-9 are disabled	Align with changes to infusion reporting workflow
F2100 r9	Q275, 279, 355	Validation (Add)	No current validation for Q275. Q279 must be answered. No current validation for Q355.	If visit is greater than or equal to 2Y, then Q275 cannot be equal to VOD/SOS option. If visit is equal to 100D, 6M or 1Y, then Q279 must be answered. If visit is greater than or equal to 2Y, then Q355 cannot be equal to hemorrhagic cystitis/hematuria.	Necessary for certain organ impairments to be disabled after the 1Y reporting period.
F2100 r9		Validation (Modify)	If Q257 contains any (BR_OBLIT, COP_BOOP, DAH, OTH_NONINF_PULM), then Q264 must be answered. If and only if Q272 = yes, then Q277 must be answered. If and only if Q319 = yes, then Q333 must be answered. If and only if Q344 = pancreatitis, then Q350 must be answered.	If Q257 contains any (BR_OBLIT, COP_BOOP, OTH_NONINF_PULM), then Q264 must be answered. If and only if Q275 = any VOD, medication toxicity, other toxicity, or unknown etiology, then Q277 must be answered. If and only if Q322 = hyperlipidemia, then Q333 must be answered. Q350 must not be answered.	Burden reduction, some organ impairments do not require a resolution date.
F2400 r10	Q12	Validation (Modify)	If and only if Q44 = any, or infusion type = allo, then Q12 must be answered	If and only if Q44 = any, then Q12 must be answered for first allo HCT and disabled for subsequent infusions	Burden reduction
F2400 r10	Q77	Validation (Modify)	If and only if Q44 = auto, then Q77 must be answered	Q77 is disabled for gene therapy infusions	Reduce duplicate reporting, as Q77 is now collected on F2003r2 (Gene Therapy Product Form).

June 2024 (released June 21, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2018 r6	Q83	Validation (Modify)	Q83 must be equal to F2402 Q401	Q83 must be equal to F2402 Q400	Correction to validation
F2402 r7		Validation (Modify)	If and only if Q91 is equal to any, then Q93 must be answered	If date received is not answered or is greater than 2024-01-26 and Q91 is equal to any, then Q93 must be answered If date received is less than or equal to 2024-01-26 and Q91 is equal to any, then Q93 is optional	Validations updated so that when edits are made to F2402s completed prior to January 2024 release, no errors will populate on unanswered MRD questions
			If and only if Q167 is equal to any, then Q169 must be answered	If date received is not answered or is greater than 2024-01-26 and Q167 is equal to any, then Q169 must be answered If date received is less than or equal to 2024-01-26 and Q167 is equal to any, then Q169 is optional
F2402 r8	Q217	Validation (Add)	If Q195 is equal to any, then Q217 must be answered	If Q195 is equal to any, then Q217 must be answered (additional subtypes added)	Data quality improvement

May 2024 (released May 17, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4100 r9	Q148	Validation (Modify)	If latest track for CT event = 15 year follow-up or standard follow-up CRF, then Q148 must be answered	If latest track for CT event = 15 year follow-up or standard follow-up CRF AND treatment path for current event = CT, then Q148 must be answered	Burden reduction, Q148 will only be answered if the combined follow-up event is a CT

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.